SFA Therapeutics, Inc
A Major Advancement in Treating Chronic Inflammatory Diseases
SFA Therapeutics is developing a 5 anti-inflammatory drugs, based on a microbiome-derived platform. Our first indication in psoriasis has FDA approval to enter phase 2; the second in liver disease is patented (Hepatitis B, NASH, & HCC). Our goal is to demonstrate proof-of-concept, then license these products to strategic partners. Eight patents filed; one issued, one allowed, one accelerated.